Triple negative (TNBC) and HER2‐positive (HER2+) tumours, conversely, more commonly harbour RB1 loss‐of‐function alterations, altered DNA damage response (DDR), near‐universal loss of TP53 function, CCNE1 and CDK4 amplifications and PTEN loss‐of‐function mutations.5, 6. This evidence concerns the gene CDK4 and neoplasm.